ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

New Hope for a Once Hopeless Diagnosis: Small Cell Lung Cancer

By: NewsUSA

(Diane Mulligan) - Small cell lung cancer (SCLC) is among the most aggressive, deadliest forms of lung cancer, yet it’s still too often overlooked. For decades, treatment options were limited, offering little hope to those diagnosed with SCLC, until now.

In 2013, Congress passed legislation that mandated the National Cancer Institute create a scientific plan for treating patients with less than a 50% chance of surviving 5 years. This included SCLC. With this focus on research, SCLC, once considered a hopeless diagnosis because of its swift spread and resistance to standard treatment, is now seeing real momentum. Breakthrough research has increased the number of treatment options by 67% giving doctors new tools and patients new reasons to hope.

Jacob SandsBecause of research, treatments like the recently FDA-approved Tarlatamab belong to a class of drugs called bispecific T-cell engagers (BiTEs), which harness the immune system to combat cancer. Another treatment, Lurbinectedin, slows or stops the growth of cancer cells in your body.  There are also next-generation approaches, such as CAR T-cell therapy and antibody-drug conjugates, and many others, now in clinical trials. Clinical trials, once a last resort, are rapidly becoming a front door to tomorrow’s breakthroughs.

Early detection is critical. Screening is the best way to find SCLC early.

Wendy Brooks knows this firsthand. Wendy had a history of lung cancer in her family. She pushed hard to get screened, and her cancer was caught early, rare for this disease. Through two clinical trials, Wendy has kept the cancer confined to her lung and is living fully. She credits screening and participating in clinical trials with saving her life.

“I’m here today because of research,” Wendy says. “I want others to know there’s hope, and clinical trials can be a lifeline.”

Thoracic oncologist Dr. Jacob Sands echoes that optimism: “I have patients more than five years out from that initial diagnosis doing great, living their lives and not on treatment. And I’ll go as far as to say that I think some patients are cured of their incurable disease.”

Lung Cancer Foundation of America (LCFA) is raising awareness of the lifesaving power of early screening, new treatments, and the growing promise of clinical trials for people facing SCLC.

LCFA is a nonprofit organization dedicated to eradicating lung cancer through research, education, and awareness programs. Committed to improving patient outcomes, donations to LCFA fund innovative research projects, educational initiatives, and advocacy for increased resources for lung cancer research.

Donate today to fight Lung Cancer at LCFAmerica.org

 

**Image Captions: 
Wendy Brooks, Lung Cancer Patient (header image)
Dr. Jacob Sands, Thoracic Oncologist at Dana-Farber Cancer Institute

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.